Entity

Time filter

Source Type

MONMOUTH JUNCTION, NJ, United States

Patent
Signum Biosciences | Date: 2012-08-03

Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chrons disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinsons disease).


Patent
Signum Biosciences | Date: 2012-12-20

The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 356.92K | Year: 2010

DESCRIPTION (provided by applicant): N-acetyl-S-famesyl-L-cysteine (AFC) and its derivatives (isoprenylcysteine (IPC) analogs) represent a novel class of topically absorbed NSAIDs whose activity is restricted to the site of application with no detectable systemic effects and no adverse affects such as skin atrophy or inhibition of wound healing. In a double- blinded, vehicle-controlled cosmetic human use study; AFC was shown to inhibit chronic skin erythema. Based on our previous work we hypothesize we can identify more potent and selective 2nd generation IPC compounds to effectively treat chronic inflammatory skin diseases associated with erythema. If it is determined that IPC analogs inhibit cytokine release induced by inflammatory or other mediators, reduce skin erythema more potently than AFC and a predictive relationship is established between in vitro and in vivo activity for IPC analogs, the feasibility of the project will have been demonstrated. Prof. Richard D. Granstein, Chairman of the Department of Dermatology at the Weill Medical College of Cornell University, and Dr. John Seykora, assistant Professor of the Department of Dermatology at the University of Pennsylvania, will contribute to this effort to successfully complete the Aims of this grant. This will lead in Phase II to a program to identify and develop novel pharmaceutical leads for the treatment of inflammatory skin diseases associated with erythema such as eczema (e.g. atopic dermatitis, seborrheic dermatitis) and rosacea. PUBLIC HEALTH RELEVANCE: Treatment for chronic inflammatory skin diseases characterized by a prominent degree of erythema, remains largely unsatisfactory and the development of more effective therapies represents a great unmet medical need. The paucity of relevant experimental models for these diseases hinder drug development efforts; thus, new treatments and screening methods to test for efficacy are required. Successful development of this novel class of topical non-steroidal anti-inflammatories will provide an important additional, and potentially better, therapeutic option for people suffering from rosacea and eczema (e.g. atopic dermatitis, seborrheic dermatitis).


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 2.98M | Year: 2011

DESCRIPTION (provided by applicant): Rosacea is a chronic dermatological condition characterized by flushing, erythema, papules, pustules, inflammatory nodules and telangiectasia. Although disease etiology remains unclear, skin inflammation has been identified as the main contributor to disease pathology. Isoprenylcysteine (IPC) analogs represent a novel class of topical anti-inflammatory compounds being developed as therapeutic agents for rosacea. As part of the Phase II SBIR project, Signum identified a lead investigational new drug (IND)-candidate, SIG990 which demonstrated strong efficacy in in vitro and in vivo models. Through pharmacokinetic and safety pharmacology studies, the preclinical safety profile for SIG990 was established. In the renewal application, we propose to continue SIG990's development path towards clinical application and FDA approval by conducting further safety assessment of drug product toxicity. Upon completion of the proposed aims, Signum will enter SIG990 into the Phase III clinical trials. PUBLIC HEALTH RELEVANCE: Rosacea is a common, chronic skin disorder afflicting people all around the world, including ~16 million Americans. Currently available treatments have yielded mixed results, often leaving patients with significant levels of facial redness and inflammatory lesions. Successful pharmaceutical development of topical IPC analog anti-inflammatories will provide an important additional, and potentially better, therapeutic option for people suffering from rosacea associated redness.


Patent
Signum Biosciences | Date: 2010-12-15

The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions

Discover hidden collaborations